Current disease status-First occurrence of the lymphoma Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the lymphoma Posts on Medivizor

Evaluating the effectiveness of lenalidomide plus rituximab for patients with recurrent or hard-to-treat DLBCL

Evaluating the effectiveness of lenalidomide plus rituximab for patients with recurrent or hard-to-treat DLBCL

Posted by on Jul 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of lenalidomide (Revlimid) plus rituximab (Rituxan) for patients with diffuse large B-cell lymphoma (DLBCL) that came back or stopped responding to treatment. This study concluded that this treatment showed some effectiveness, but adding other agents may improve outcomes for these...

Read More

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Posted by on Jun 6, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether brentuximab vedotin (Adcedris; BC) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combination resulted in a reduction or elimination of consolidative radiotherapy in early-stage unfavorable-risk Hodgkin lymphoma (HL). The data showed that the BV+AVD combination with and without...

Read More

Evaluating the safety and effectiveness of brentuximab vedotin for children with high-risk Hodgkin lymphoma.

Evaluating the safety and effectiveness of brentuximab vedotin for children with high-risk Hodgkin lymphoma.

Posted by on May 23, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of incorporating brentuximab vedotin (BV; Adcetris) as a substitution for vincristine in the OEPA (vincristine, etoposide, prednisone, doxorubicin) or COPD (cyclophosphamide, vincristine, prednisone, dacarbazine) chemotherapy regimen in children with high-risk classical...

Read More

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Apr 18, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of inotuzumab ozogamicin (Besponsa; INO) in patients with relapsed/refractory (r/r) acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The data showed that the treatment had good effectiveness and manageable side effects for these patients. Some background A high number...

Read More

How effective is idarubicin-substituted BEAC (IEAC) as a conditioning regimen for patients with B-cell non-Hodgkin’s lymphoma undergoing ASCT?

How effective is idarubicin-substituted BEAC (IEAC) as a conditioning regimen for patients with B-cell non-Hodgkin’s lymphoma undergoing ASCT?

Posted by on Apr 4, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the BEAC (BCNU, etoposide, cytarabine, and cyclophosphamide) and IEAC (idarubicin, etoposide, cytarabine, and cyclophosphamide) regimens before autologous stem cell transplantation (ASCT) in patients with relapsed/refractory (r/r) and aggressive B-cell non-Hodgkin lymphoma (NHL). The study found that IEAC regimen...

Read More

Treatment of primary central nervous system lymphoma: high-dose methotrexate alone or with additional therapy?

Treatment of primary central nervous system lymphoma: high-dose methotrexate alone or with additional therapy?

Posted by on Feb 27, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The aim of this study was to evaluate high-dose (HD) methotrexate (MTX; Trexall) alone and in combination with other therapies for the treatment of primary central nervous system (CNS) lymphoma (PNCSL). The study found that HD-MTX in combination with other chemotherapies was most effective for these patients. Some background...

Read More

Evaluating outcomes for patients with follicular lymphoma after prolonged rituximab maintenance therapy

Evaluating outcomes for patients with follicular lymphoma after prolonged rituximab maintenance therapy

Posted by on Feb 6, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated different rituximab schedules in patients with follicular lymphoma (FL) and reported their long-term treatment outcomes. The data showed that rituximab treatment alone on a standard schedule improves the long-term outcomes of these patients. Some background Follicular lymphoma (FL) is a type of non-Hodgkin...

Read More

Effects of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma in a resource-limited country

Effects of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin lymphoma in a resource-limited country

Posted by on Dec 6, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The study analyzed outcomes of high-dose therapy (HDT) with autologous hematopoietic stem cell transplantation (AHSCT) for patients with non-Hodgkin lymphoma (NHL) in a resource-limited country and evaluated whether upfront AHSCT could be an effective treatment. The authors found promising outcomes of this treatment in a resource-limited...

Read More

Does first-line treatment with R-CHOP benefit patients with grade 3A follicular lymphoma?

Does first-line treatment with R-CHOP benefit patients with grade 3A follicular lymphoma?

Posted by on Aug 30, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to compare the effectiveness of 2 drug regimens for patients with grade 3A follicular lymphoma (FL3A). The authors concluded that R-CHOP has a benefit over RB in the treatment of these patients. Some background Follicular lymphoma (FL) is the most common type of non-Hodgkin lymphoma (NHL).FL usually has good...

Read More

How does ABVD chemotherapy affect the fertility of female patients with Hodgkin lymphoma?

How does ABVD chemotherapy affect the fertility of female patients with Hodgkin lymphoma?

Posted by on Jun 27, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined if ABVD chemotherapy impacted fertility in female patients with Hodgkin lymphoma (HL). The authors found that ABVD reduced the levels of one of the fertility hormones and the type of fertility treatment patients opted for was not affected by ABVD. Some background Many patients with HL are young and fertility...

Read More